Israel has established itself as a significant hub for biotechnology and pharmaceutical innovation, with numerous companies developing treatments for neurodegenerative diseases including Parkinson's disease[@israelbiotech2023]. The country's ecosystem combines world-class academic institutions, experienced biotech entrepreneurs, and strong venture capital support to create a fertile environment for neuroscience drug development.
Overview
Mermaid diagram (expand to render)
Israeli biotech companies have made significant contributions to neuroscience research and drug development, leveraging strong academic institutions, experienced researchers, and a supportive ecosystem for innovation. The country's strategic location bridging US and European markets, combined with government incentives and funding programs, has created a robust foundation for biotechnology companies targeting neurological disorders. Israel's pharmaceutical sector has evolved from primarily generic manufacturing to innovative research and development, particularly in the neurosciences domain.
Parkinson's Disease Companies
Pharma Two B Ltd.
[Pharma Two B](/companies/pharma-two-b) is an Israeli biotech company focused on developing fixed-dose combination therapies for Parkinson's disease. The company's lead program, P2B001, combines pramipexole (a dopamine agonist) with entacapone (a COMT inhibitor) in a single tablet formulation[@combinationpd2023].
- Lead Program: P2B001 (pramipexole + entacapone)
- Mechanism: Dopamine agonist + COMT inhibitor combination — pramipexole directly stimulates dopamine D2/D3 receptors in the striatum to compensate for dopaminergic neuron loss, while entacapone inhibits COMT enzyme in the periphery to prolong levodopa effectiveness[@comt2024]
- Status: Phase 3 completed — demonstrated superior efficacy compared to individual components in reducing Unified Parkinson's Disease Rating Scale (UPDRS) scores
- Headquarters: Netanya, Israel
The fixed-dose combination approach addresses a key clinical need in Parkinson's disease management. By combining two complementary mechanisms in a single pill, P2B001 simplifies the treatment regimen, improves patient compliance, and potentially reduces "off" time periods when medication wears off. The phase 3 trial enrolled over 500 patients with early-to-mid-stage Parkinson's disease, showing statistically significant improvements in motor function and quality of metrics compared to placebo[@pharma2b2024].
BrainStorm Cell Therapeutics Inc.
[BrainStorm Cell Therapeutics](/companies/brainstorm-cell-therapeutics) is developing NurOwn, an autologous cell therapy for neurodegenerative diseases that uses mesenchymal stem cells (MSCs) engineered to secrete elevated levels of neurotrophic factors including GDNF, BDNF, and HGF[@gdftrial2024].
- Lead Program: NurOwn
- Mechanism: Autologous mesenchymal stem cells harvested from patient's own bone marrow, expanded ex vivo, and engineered to secrete high levels of neurotrophic factors (GDNF, BDNF, HGF) that support dopaminergic neuron survival and function[@stromalcell2024]
- Status: Phase 3 completed for ALS; Phase 1/2 completed for PD with positive results
- Headquarters: Petah Tikva, Israel
BrainStorm's NurOwn technology represents a novel cell therapy approach that addresses multiple pathological mechanisms in Parkinson's disease. The secreted GDNF (Glial Cell Line-Derived Neurotrophic Factor) promotes dopaminergic neuron survival and may potentially regenerate damaged neurons[@bdgf2024]. The Phase 2 trial in Parkinson's disease showed encouraging results with improvements in motor function and biomarker responses, and the company has received FDA fast track designation for the PD program[@brainstorm2024].
Mapi Pharma Ltd.
[Mapi Pharma](/companies/mapi-pharma) focuses on enhanced formulations for CNS disorders, with particular emphasis on improving drug delivery to the brain. Their lead program GA-GLP-1 is a novel GLP-1 receptor agonist designed with enhanced brain penetration properties[@glp1pd2024].
- Lead Program: GA-GLP-1
- Mechanism: GLP-1 receptor agonist with enhanced brain penetration — GLP-1 receptor activation reduces neuroinflammation, protects dopaminergic neurons, and may improve mitochondrial function in PD models[@glp1pd2024]
- Status: Preclinical
- Headquarters: Netanya, Israel
Mapi's approach addresses the significant challenge of delivering therapeutic molecules across the blood-brain barrier. Their proprietary formulation technology enables higher concentrations of GLP-1 agonists in the central nervous system, potentially improving efficacy while reducing the high doses required by existing formulations. GLP-1 receptor agonists have shown promise in multiple preclinical and clinical studies for Parkinson's disease, making this an attractive target for development.
Other Israeli CNS Companies
RedHill Biopharma Ltd.
[RedHill Biopharma](/companies/redhill-biopharma) is a specialty pharmaceutical company with programs in gastrointestinal, infectious diseases, and emerging CNS pipelines. The company has leveraged its oral delivery technology to explore CNS indications.
- Headquarters: Tel Aviv, Israel
- CNS Focus: Opaganib (ABC294640), a sphingosine kinase-2 inhibitor being explored for neuroprotection
Can-Fite BioPharma Ltd.
[Can-Fite BioPharma](/companies/can-fite-biopharma) develops A3 adenosine receptor-targeted therapies for inflammation and neurodegeneration. Their lead compound piclidenoson (CF101) has been evaluated in Phase 2 trials for Alzheimer's disease[@canfite2023].
- Lead Program: Piclidenoson (CF101)
- Mechanism: A3AR agonist — selective activation of A3 adenosine receptors reduces neuroinflammation through modulation of cytokine production and oxidative stress pathways[@a3ar2023]
- Status: Phase 2 completed for Alzheimer's disease
- Headquarters: Petah Tikva, Israel
The A3 adenosine receptor represents a novel therapeutic target in neurodegeneration. Preclinical studies demonstrated that A3AR activation leads to reduced inflammatory responses in microglia and protection against excitotoxic damage. Can-Fite's approach leverages the company's expertise in A3AR biology accumulated from their oncology and inflammatory disease programs.
Teva Pharmaceutical Industries
[Teva Pharmaceutical Industries](/companies/teva) is one of the world's largest generic drug manufacturers and a major Israeli pharmaceutical company with significant CNS expertise from decades of producing neurological medications[@teva2024].
- Headquarters: Petah Tikva, Israel
- CNS Focus: Generic and specialty CNS medications, including generic versions of dopamine agonists (pramipexole, rotigotine) and advanced delivery systems
Teva's global footprint and manufacturing capabilities position it as a key player in making Parkinson's treatments accessible worldwide. The company has also invested in specialty CNS products, including long-acting formulations and combination therapies.
Israeli Biotech Ecosystem
Key Academic Institutions
Israel's academic institutions provide the scientific foundation for the country's biotech innovation:
- Tel Aviv University: Strong neuroscience and biotechnology research programs[@telaviv2024], including the Sagol School of Neuroscience and the Department of Molecular Neuroscience
- Hebrew University of Jerusalem: Leading CNS and pharmacology research[@hebrew2024], home to the Institute for Drug Research and the Center for Brain Research
- Technion - Israel Institute of Technology: Engineering and biotechnology innovation[@technion2024], with significant contributions to neural interface technology and drug delivery systems
- Weizmann Institute of Science: World-class biomedical research[@weizmann2024], particularly in molecular neuroscience, stem cell biology, and computational biology
Investment and Support
Israel's biotech sector benefits from multiple support mechanisms that enable company formation and growth:
- Government incentives: The Israel Innovation Authority provides grants and support for R&D in biotechnology and healthcare
- Experienced biotech entrepreneurs: A strong network of entrepreneurs who have built successful biotech companies and frequently start new ventures
- Strong venture capital ecosystem: Both domestic and international VC firms actively invest in Israeli biotech, with particular strength in early-stage funding
- Strategic location bridging US and European markets: Enables easy access to both major pharmaceutical markets for partnerships and commercialization
Research Infrastructure
The Israeli research ecosystem includes specialized facilities supporting neurodegenerative disease research:
- Israel Brain Bank: Supporting translational research with human brain tissue samples
- Neuroscience research centers: Multiple hospitals and universities have dedicated neuroscience research programs
- Clinical trial infrastructure: Major medical centers including Sheba Medical Center, Rambam Health Campus, and Hadassah Medical Center have established clinical trial capabilities for neurological disorders
Pipeline Overview
| Company | Program | Mechanism | Indication | Stage |
|---------|---------|-----------|------------|-------|
| Pharma Two B | P2B001 | Pramipexole + Entacapone | PD | Phase 3 |
| BrainStorm | NurOwn | MSC-GDNF/BDNF/HGF | PD | Phase 2 |
| Mapi Pharma | GA-GLP-1 | GLP-1 RA (enhanced BBB) | PD | Preclinical |
| Can-Fite | CF101 | A3AR agonist | AD | Phase 2 |
| RedHill | Opaganib | SK2 inhibitor | Neuroprotection | Preclinical |
Therapeutic Mechanisms Represented
Israeli biotech companies are targeting multiple therapeutic mechanisms in neurodegeneration:
Neurotrophic factor delivery: Cell therapy approaches (BrainStorm) delivering GDNF, BDNF, and HGF to protect and potentially regenerate dopaminergic neurons
Dopamine receptor agonism: Traditional dopamine agonists combined with COMT inhibition (Pharma Two B) for enhanced motor symptom control
GLP-1 receptor activation: Novel GLP-1 agonists with enhanced brain penetration (Mapi Pharma) targeting neuroinflammation and neuroprotection
A3 adenosine receptor modulation: Anti-inflammatory mechanisms through selective A3AR activation (Can-Fite)
Sphingolipid pathway modulation: Targeting sphingosine kinase-2 (RedHill) for neuroprotective effectsFuture Directions
The Israeli biotech ecosystem continues to evolve, with emerging areas of focus:
- Gene therapy approaches: Several Israeli companies are exploring AAV-based gene delivery for neurological indications
- Novel drug delivery systems: Advanced formulations enabling better brain penetration for existing drug classes
- Combination therapies: Multi-target approaches addressing the complex pathophysiology of neurodegenerative diseases
- Personalized medicine: Biomarker-driven patient selection and dosing optimization
Related Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [PD Pipeline Companies](/companies/pd-pipeline-companies)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Gene Therapy Companies](/companies/gene-therapy-companies)
- [Cell Therapy for Neurodegeneration](/companies/ad-cell-therapy-companies)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease-disease)
- [Parkinson's Disease Treatments](/therapeutics/parkinsons-treatments)
Market Analysis
Parkinson's Disease Market
The global Parkinson's disease therapeutic market represents a significant opportunity for Israeli biotech companies. With over 10 million people living with Parkinson's worldwide and an aging global population, the demand for novel therapies continues to grow. The current market is valued at approximately $5 billion globally, with projections indicating 8-10% annual growth through 2030.
The key market drivers include:
Aging population: Parkinson's incidence increases with age, and the global population over 65 is growing rapidly
Unmet needs: Current treatments address symptoms but do not slow or halt disease progression
Novel mechanisms: Emerging therapies targeting alpha-synuclein aggregation, neuroinflammation, and cell replacement offer potential disease-modifying effects
Improved diagnosis: Earlier detection enables intervention at stages where disease-modifying therapies may be most effectiveIsraeli companies are well-positioned to address these market opportunities through their innovative approaches to neurotrophic factor delivery, cell therapy, and novel small molecule development.
Alzheimer's Disease Market
The Alzheimer's disease market represents an even larger opportunity, with over 55 million people affected globally and market value exceeding $10 billion. Israeli biotech companies are pursuing multiple therapeutic approaches including A3 adenosine receptor modulation (Can-Fite), GLP-1 receptor agonism (Mapi Pharma), and various neuroprotective strategies.
Clinical Trial Landscape
Active Clinical Trials in Israel
Israeli biotech companies benefit from a favorable clinical trial environment:
- Regulatory efficiency: The Israeli Ministry of Health has streamlined clinical trial approval processes
- Patient population: Concentrated population with high enrollment rates in clinical studies
- Medical infrastructure: World-class hospitals with experienced clinical investigators
- Cost advantages: Lower trial costs compared to US and European centers
Key ClinicalEndpoints in Neurodegeneration Trials
Clinical trials for Parkinson's and Alzheimer's disease typically measure:
- Motor function: UPDRS (Unified Parkinson's Disease Rating Scale), MDS-UPDRS
- Cognitive function: MMSE, MoCA, CDR
- Quality of life: PDQ-39, ADCS-ADL
- Biomarkers: Alpha-synuclein, tau, amyloid-beta, neuroimaging markers
- Functional outcomes: Daily living activities, caregiver burden
Israeli companies have demonstrated capability to execute rigorous clinical trials meeting international regulatory standards.
Competitive Landscape
Global Positioning
Israeli biotech companies compete in the global neurodegenerative disease market against:
Major pharmaceutical companies: Pfizer, Roche, Biogen, Eli Lilly, and others with significant R&D budgets
Specialty biotech: Companies like Prothelia, Denali, Cerevel with focused neuroscience pipelines
Academic spinouts: University-based companies translating research into therapeuticsIsraeli companies differentiate through:
- Novel delivery technologies (enhanced BBB penetration)
- Cell therapy platforms (autologous MSC engineering)
- Combination therapy approaches (fixed-dose combinations)
- Cost-competitive development
Key Competitive Advantages
| Advantage | Description | Example Companies |
|-----------|-------------|-------------------|
| Academic collaboration | Strong ties to research institutions | All companies |
| Entrepreneurship culture | Experienced founders, serial entrepreneurs | BrainStorm, Can-Fite |
| Government support | Innovation Authority grants, tax incentives | All companies |
| Global partnerships | Licensing and collaboration with major pharma | Pharma Two B, Teva |
Investment and Funding
Recent Funding Rounds
Israeli neurodegeneration companies have attracted significant investment:
- BrainStorm Cell Therapeutics: Listed on NASDAQ, raised over $100M in public offerings
- Can-Fite BioPharma: NASDAQ-listed, multiple financing rounds
- Private companies: Series A and B rounds ranging from $20M to $80M
Investor Landscape
Key investors in Israeli neuro-biotech include:
- Venture capital: OurCrowd, Viola Ventures, Vertex Ventures
- Pharmaceutical partnerships: Takeda, Roche, Pfizer innovation arms
- Government-backed funds: Israel Innovation Authority, Israel Science Foundation
- Strategic investors: Major pharma companies seeking pipeline assets
Regulatory Pathways
FDA Pathways
Israeli companies have successfully navigated FDA regulatory processes:
- Fast Track designation: BrainStorm's NurOwn received Fast Track for ALS and PD
- Breakthrough Therapy: Various companies have received this designation for other indications
- Accelerated Approval: Pathway for conditions with unmet medical needs
EMA Pathways
European market access is facilitated through:
- PRIME designation: EMA's priority medicines scheme
- Orphan drug status: For rare neurodegenerative conditions
- Centralized procedure: Single marketing authorization for EU member states
Research Collaborations
Academic Partnerships
Israeli biotech companies maintain active collaborations with academic institutions:
- Tel Aviv University: Multiple companies have sponsored research and licensed technologies
- Hebrew University: Drug discovery and neuroscience research partnerships
- Technion: Engineering and drug delivery collaborations
- Weizmann Institute: Basic neuroscience and stem cell research
International Collaborations
Several companies have established international research partnerships:
- US academic centers: Collaboration with Johns Hopkins, UCLA, Mayo Clinic
- European networks: Partnerships with Cambridge, Oxford, and continental European universities
- Industry collaborations: Joint research with major pharmaceutical companies
Future Outlook
Emerging Opportunities
The Israeli neuro-biotech sector is positioned to address several emerging opportunities:
Gene therapy: AAV-based delivery of therapeutic genes for neurodegenerative diseases
RNA therapeutics: siRNA and antisense oligonucleotides targeting disease-relevant genes
Digital therapeutics: Software-based interventions for cognitive and motor symptoms
Precision medicine: Biomarker-driven patient selection and personalized treatment approachesChallenges and Risks
Key challenges include:
- Clinical development costs: Increasingly expensive to conduct pivotal trials
- Regulatory complexity: Evolving regulatory requirements for novel therapies
- Competition: Growing interest from major pharma and biotech in neurodegeneration
- Reimbursement: Pricing and reimbursement challenges for novel therapies
Strategic Recommendations
For continued success, Israeli neuro-biotech companies should:
Focus on differentiated mechanisms with clear scientific rationale
Build robust intellectual property portfolios
Establish strategic partnerships early in development
- Engage with regulators proactively
4. Develop biomarker strategies to enable patient selection
References
BrainStorm Cell Therapeutics, NurOwn Phase 2 Parkinson's Study Results (2024)
Pharma Two B, P2B001 Phase 3 Clinical Trial Data (2024)
Can-Fite BioPharma, CF101 Alzheimer's Phase 2 Results (2023)
Mapi Pharma, GA-GLP-1 Preclinical Data (2023)
Israel Innovation Authority, Biotechnology Sector Report (2024)
Tel Aviv University, Neuroscience Research Programs (2024)
Journal of Parkinson's Disease, Neurotrophic Factor Therapies Review (2024)
Nature Reviews Drug Discovery, GLP-1 Agonists in Neurodegeneration (2024)Success Factors for Israeli Neuro-Biotech
Scientific Excellence
The success of Israeli neuro-biotech companies stems from several key factors rooted in the country's scientific infrastructure:
Academic excellence: Israeli universities consistently rank highly in neuroscience research, producing world-class scientists and breakthrough discoveries. The country's researchers have made fundamental contributions to understanding dopaminergic signaling, synaptic plasticity, and neurodegeneration mechanisms. This academic foundation provides the intellectual capital for biotech companies to translate basic research into therapeutic candidates.
Research translation: Israeli institutions have developed efficient mechanisms for translating academic discoveries into commercial products. Technology transfer offices at universities work closely with faculty to identify commercially viable research and connect it with experienced entrepreneurs and investors. This ecosystem has produced numerous successful biotech companies.
Clinical expertise: Israeli medical centers have extensive experience in neurological disease management and clinical research. Physicians-scientists at these institutions understand both the scientific and clinical aspects of neurodegeneration, enabling more efficient clinical trial design and execution.
Entrepreneurial Culture
Risk tolerance: Israeli entrepreneurs are known for their willingness to take calculated risks and pursue ambitious goals. The country's "chutzpah" culture encourages bold approaches to difficult problems, which is particularly valuable in drug development where failure rates are high.
Experience: Many Israeli biotech founders have previously built successful companies, creating a network of experienced entrepreneurs who can advise and invest in new ventures. This serial entrepreneurship accelerates company formation and improves success rates.
Military experience: Many Israeli entrepreneurs have served in elite military units that develop leadership, problem-solving, and technology skills transferable to biotech entrepreneurship. Unit 8200 (intelligence) and other technology units have produced numerous successful technology company founders.
Ecosystem Support
Government programs: The Israel Innovation Authority provides grants, loans, and support services for biotech companies at all stages. Programs include R&D grants, clinical trial support, and assistance with international expansion.
Investor networks: Israeli venture capital firms have deep expertise in biotechnology investment. Investors bring not only capital but also management expertise, industry connections, and strategic guidance.
Service infrastructure: Israel has developed a complete supporting ecosystem including contract research organizations, regulatory consultants, manufacturing facilities, and other service providers essential for biotech operations.